Replimune reported early-October commercial availability of TUDRIQEV with institutional formulary and prescription activity, while Nautilus Biotechnology launched an Early Access Program for the Nautilus Voyager platform.

Customer gains accompanied higher adjusted earnings and stronger annual adjusted EPS outlooks at AT&T and Verizon.

CSX, Norfolk Southern and Union Pacific reported stronger third-quarter demand, but margin performance diverged.

Lockheed Martin and RTX describe customer support for munitions investment, while Northrop expects operating and tax offsets to absorb heavier B-21 spending.

The clearance gave adults with Crohn’s disease an option to start Skyrizi at home and continue using an on-body injector through maintenance treatment.

The filing covers up to 50.2 million shares for resale; ALBC is already quoted on the OTCQB.

Three issuers reported product launches in this week's filings, from a Virginia fab line to an intended Panama prescription route.

Micron began first production of 1α DDR4 in Virginia, while Tilray launched a prescription CBD oral solution in Panama.

The company paired its latest glasses release with an Indian brand ambassador and plans for more hands-free AI features.

The cloud services provider extended its academy network to prepare local technicians for an infrastructure business that depends on skilled workers.

The furniture maker’s Loved by Lovesac program is now live in a limited set of markets after a June 2025 debut.